

A Synthesis of Optically Active *cis* and *trans* 2-(5-Hydroxypiperidin-2-yl)acetates

P. N. Reddy, Sang-soo Han, and Kyoo-hyun Chung*

Department of Chemistry, Inha University, Incheon 402-751, Korea

Received March 21, 1998


In dealing with stereochemical issues in the synthesis of antitumor agent DKP 593A, isolated from the soil micro-organism *Streptomyces griseoluteus*,¹ the stereochemistry of 2,5-disubstituted piperidines should be controlled. Many of them are found as biologically active compounds in nature, such as streptolutin and pseudoconhydrine.²

2-(5-Hydroxypiperidin-2-yl)acetate would be a common intermediate in the preparation of hydroxyhomopipecollic acid and pseudoconhydrine.³ In this paper, we would like to report a synthesis of *cis* and *trans* 2-[5-(*t*-butyldimethylsilyloxy)piperidin-2-yl]acetates from (*S*)-5-hydroxy-2-oxopiperidine (**1**) which was readily available from L-glutamic acid.⁴


Hydroxy group of **1** was protected by *t*-butyldimethylsilyl group to give silyloxy lactam **2**. The lactam **2** was treated with trimethyloxonium tetrafluoroborate and the resulting imino methyl ether was condensed with Meldrum's acid to afford adduct **3**. The resulting adduct was reacted with NaOMe in MeOH at refluxing temperature to give conjugated ester **4**.⁵ Herdeis and coworkers also prepared the corresponding ethyl ester of compound **4** from an intermediate in the preparation of (*S*)-5-hydroxy-2-oxopiperidine (**1**), while we are preparing this manuscript.^{3c} In the preparation of **4**, yield and the number of steps are almost same in both methods.

Reduction of **4** gave a mixture of *cis* and *trans* ester **5** which was separated by column chromatography (Scheme 1). The ratio of the *cis* to *trans* isomer was about 20:1 by hydrogenation on 10% Pd/C,^{3c} and 4:6 by NaBH₃CN. Herdeis also prepared a derivative of **5** using different method from **1**, which gave the mixture of *trans* and *cis* isomers in a ratio of 3:1.^{3a}

On the other hand, the adduct **3** was reacted with NaBH₄ and then the resulting mixture was treated with 6 N HCl at 110 °C to give a mixture of *cis* and *trans* 5-hydroxyhomo-



Scheme 1. ^a *t*-BuMe₂SiCl, imidazole. ^b i) Me₃OBF₄, ii) Meldrum's acid, Et₃N. ^c NaOMe, MeOH, Δ. ^d H₂, 10% Pd/C, 3 atm.



Scheme 2. ^a cbz-Cl, Et₃N. ^b i) 6 N HCl, ii) NaH, CS₂, MeI. ^c AIBN, (nBu)₃SnH, xylene, Δ. ^d (Boc)₂O, H₂, 10% Pd/C.

pipecolic acids.^{3b} The stereochemistry of the *cis* and *trans* isomers could be assigned by ¹H NMR, and indirectly confirmed by comparison with the optical rotation of a known compound.⁸

The isomer, which has a lower R_f value on TLC (5% MeOH/CH₂Cl₂), was reacted with benzyl chloroformate^{3c} and then treated with 6 N HCl to give desilylated alcohol. Removal of the alcohol moiety was done by a sequence; i.e. conversion of the alcohol to xanthate **7a** and cleavage of the xanthate with AIBN and (nBu)₃SnH.⁶ The resulting methyl 2-(*N*-benzyloxycarbonyl)piperidineacetate (**8**)⁷ was hydrogenated on 10% Pd/C in the presence of di-*t*-butylcarbonate to give methyl 2-(*N*-*t*-butyloxycarbonyl)piperidineacetate [**9**, [α]_D²⁰ = -8.1 (c 0.1, CHCl₃)], which could be assigned *S* form in comparison with the reported specific rotation [lit.⁸ [α]_D²⁰ = -8.3 (c 0.54, CHCl₃)]. In consequence, the stereochemistry of the isomer was *cis* because both substituents on the piperidine ring have *S* configuration (Scheme 2). This result is consistent with X-ray analysis.^{3b}

Using this methodology, 2-alkylpiperidines such as coniine and hygrine could be synthesized as an optically active form.²

In conclusion, 2-(5-hydroxy)piperidineacetate can be synthesized via Meldrum's acid adduct. Control of the *trans* stereochemistry is currently in progress and the diastereoselective reaction on the side chain will be also studied for the synthesis of streptolutin.⁹

Acknowledgment. This work was supported in part by the Organic Chemistry Research Center-the Korean Science and Engineering Foundation. We thank Inha University for providing financial support to Dr. P. N. Reddy as postdoctoral fellowship.

References

- (a) Fukuyama, T.; Frank, R. K.; Jewell, C. F. *J. Am. Chem. Soc.* **1980**, *102*, 2122. (b) Golding, B. T.; Smith, A. J. *J. C. S. Chem. Commun.* **1980**, 702.

2. (a) Enders, D.; Hassel, T.; Pieter, R.; Renger, B.; Seebach, D. *Synthesis* **1976**, 548. (b) Handling, K. E.; Burks, S. R. *J. Org. Chem.* **1984**, 49, 40. (c) Shono, T.; Matsumura, Y.; Onomura, O.; Sato, M. *J. Org. Chem.* **1988**, 53, 4118. (d) Oppolzer, W.; Bochet, C. G. *Tetrahedron Lett.* **1995**, 36, 2959. (e) Moody, C. J.; Lightfoot, A. P.; Gallagher, P. T. *J. Org. Chem.* **1997**, 62, 746. (f) Fry, D. F.; Brown, M.; McDonald, J. C.; Dieter, R. K. *Tetrahedron Lett.* **1996**, 37, 6227.
3. (a) Herdeis, C.; Held, W. A.; Schwabenlander, F.; Kirfel, A. *Liebigs Ann. Chem.* **1995**, 1295. (b) Herdeis, C.; Held, W. A.; Kirfel, A.; Schwabenlander, F. *Tetrahedron* **1996**, 52, 6409. (c) Herdeis, C.; Schfter, T. *Synthesis* **1997**, 1405.
4. Herdeis, C. *Synthesis* **1986**, 232.
5. Celerier, J.-P.; Deloisy, E.; Lhommet, G.; Maitte, P. *J. Org. Chem.* **1979**, 44, 3089.
6. (a) Crich, D.; Beckwith, A. L. J.; Chem, C.; Yao, A.; Davison, I. G. E.; Longmore, R. W.; De Parrodi, C. A.; Quintero-cortes, L.; Sandoval-ramirez, J. *J. Am. Chem. Soc.* **1995**, 117, 8757. (b) Sharma, R.; Lubell, W. D. *J. Org. Chem.* **1996**, 61, 202.
7. Chung, K.-H.; An, S.-O. *J. Korean Chem. Soc.* **1995**, 39, 431.
8. Morley, C.; Knight, D. W.; Share, A. C. *Tetrahedron: Asymmetry* **1990**, 1, 147.
9. **Experiment.** ^1H NMR and ^{13}C NMR spectra were recorded on a Varian Gemini 2000 (200 MHz) spectrometer in CDCl_3 . Chemical shifts for ^1H and ^{13}C NMR spectra were reference to TMS and measured with respect to the residual protons in CDCl_3 . Melting points were measured on a Yamato MP-21 and were uncorrected. Elemental analysis were performed by OCRC at Sogang University in Seoul, Korea.
(5S)-*t*-Butyldimethylsilyloxy-2-oxopiperidine (2); mp 46-47 °C. ^1H NMR δ 0.04 (s, 6H, Si-Me), 0.85 (s, 9H, *t*-Bu), 1.80-2.00 (m, 2H, H_4), 2.22-2.39 (m, 1H, H_{3a}), 2.48-2.68 (m, 1H, H_{3c}), 3.12-3.26 (m, 1H, H_{6a}), 3.33-3.45 (m, 1H, H_{6c}), 4.07 (m, 1H, H_{5c}), 6.50 (bs, 1H, N-H). ^{13}C NMR δ -6.64, 16.2, 23.9, 25.7, 27.1, 47.5, 62.3, 170.7.
Anal. Calcd for $\text{C}_{11}\text{H}_{23}\text{NO}_2\text{Si}$: C, 57.64; H, 10.04; N, 6.11. Found; C, 57.36; H, 10.72; N, 6.10.
2,2-Dimethyl-5-[2-(5S)-(*t*-butyldimethylsilyloxy)piperidin-2-ylidene]-1,3-dioxane-4,6-dione (3). **Meldrum's Acid adduct 3;** mp 125-126 °C. ^1H NMR δ 0.05 (s, 6H, Si-Me), 0.84 (s, 9H, *t*-Bu), 1.64 (s, 6H, Me), 1.76-1.91 (m, 2H, H_4), 3.23-3.86 (m, 4H, H_3 , H_6), 4.11 (m, 1H, H_{5a}), 11.5 (bs, 1H, N-H). ^{13}C NMR δ -4.8, 18.0, 25.7, 25.8, 26.4, 26.8, 49.3, 62.6, 83.1, 102.3, 162.3, 167.5, 173.7. **Anal.** Calcd for $\text{C}_{17}\text{H}_{29}\text{NO}_5\text{Si}$: C, 57.43; H, 8.22; N, 3.94. Found; C, 57.56; H, 8.22; N, 3.85.
Methyl 2-[(5S)-5-(*t*-butyldimethylsilyloxy)piperidin-2-ylidene]acetate (4).^{3c} ^1H NMR δ 0.05, 0.07 (s, 6H, Si-Me), 0.88 (s, 9H, *t*-Bu), 1.58-1.78 (m, 1H, H_{4a}), 1.78-1.93 (m, 1H, H_{4c}), 2.20-2.40 (m, 1H, H_{3a}), 2.50-2.70 (m, 1H, H_{3c}), 3.02-3.16 (m, 1H, H_{6a}), 3.34-3.48 (m, 1H, H_{6c}), 3.62 (s, 3H, OMe), 3.97-4.10 (m, 1H, H_{5a}), 4.41 (s, 1H, Olefin-H), 8.61 (bs, 1H, N-H). ^{13}C NMR δ -6.60, 16.2, 23.9, 24.4, 27.1, 46.7, 48.1, 63.5, 78.1, 160.2, 169.3.
Methyl 2-[(2S, 5S)-5-(*t*-butyldimethylsilyloxy)piperidin-2-yl]acetate (5a); ^1H NMR δ 0.00, 0.05 (s, 6H, Si-Me), 0.82 (s, 9H, *t*-Bu), 1.35-1.93 (m, 4H, H_3 , H_4), 2.20-2.40 (m, 2H, H), 2.64-3.00 (m, 3H, H_6 , N-H), 3.64 (s, 3H, OMe), 3.68 (m, 1H, H_{5c}). ^{13}C NMR δ -6.68, 16.3, 24.0, 25.2, 29.8, 39.6, 49.7, 50.9, 51.3, 63.0, 170.8.
Methyl 2-[(2R, 5S)-5-(*t*-butyldimethylsilyloxy)piperidin-2-yl]acetate (5b); ^1H NMR δ 0.03 (s, 6H, Si-Me), 0.86 (s, 9H, *t*-Bu), 1.14-1.48 (m, 2H, H_4), 1.86-2.00 (m, 2H, H_3), 2.24-2.56 (m, 3H, H_{6a} , H), 2.76-2.92 (m, 1H, H_{2a}), 3.02-3.14 (m, 1H, H_{6c}), 3.50-3.68 (m, 1H, H_{5a}), 3.68 (s, 3H, OMe). ^{13}C NMR δ -6.46, 16.4, 24.1, 29.6, 32.6, 38.9, 49.8, 50.7, 52.4, 67.1, 171.1.
Xanthate 7a; ^1H NMR δ 1.70-1.92 (m, 2H, H_1), 2.05-2.23 (m, 2H, H_4), 2.55 (s, 3H, SMe), 2.50-2.76 (m, 2H, H_a), 2.92 (dd, $J_{\text{gem}}=13$ Hz, $J_{\text{vic}}=10.8$ Hz, 1H, H_{6a}), 3.61 (s, 3H, OMe), 4.39-4.57 (m, 1H, H_{6c}), 5.14 (s, 2H, benzyl), 5.36-5.55 (m, 1H, H_{5a}), 7.34 (bs, 5H, phenyl). ^{13}C NMR δ 17.4, 22.9, 24.7, 33.2, 40.2, 45.8, 50.0, 65.8, 75.4, 126.2, 126.4, 126.8, 134.8, 153.4, 169.4, 213.3.